These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17876040)

  • 1. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
    Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
    Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
    Wickström M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknäs M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
    Biochem Pharmacol; 2010 May; 79(9):1281-90. PubMed ID: 20067771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
    Wickström M; Haglund C; Lindman H; Nygren P; Larsson R; Gullbo J
    Invest New Drugs; 2008 Jun; 26(3):195-204. PubMed ID: 17922077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
    Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; De La Torre M; Luthman K; Larsson R
    Invest New Drugs; 2004 Nov; 22(4):411-20. PubMed ID: 15292711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
    Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
    Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
    Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
    Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
    Taylor JS; Yavuz B; Zeki J; Wood L; Ikegaki N; Coburn J; Harrington K; Shimada H; Kaplan DL; Chiu B
    Surgery; 2020 Jun; 167(6):969-977. PubMed ID: 32122657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.
    Mendonça-Torres MC; Roberts SS
    Cancer Biol Ther; 2013 Apr; 14(4):319-26. PubMed ID: 23358477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
    Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
    Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
    Geng X; Xie L; Xing H
    Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Pritchard J; Meller S; Lewis I; Kingston J; McElwain T
    Eur J Cancer; 1992; 28A(8-9):1324-8. PubMed ID: 1515243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
    Keshelava N; Seeger RC; Groshen S; Reynolds CP
    Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
    Lange B; Schroeder U; Huebener N; Jikai J; Wenkel J; Strandsby A; Wrasidlo W; Gaedicke G; Lode HN
    Cancer Lett; 2003 Jul; 197(1-2):225-30. PubMed ID: 12880986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
    J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
    Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
    Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
    Keshelava N; Seeger RC; Reynolds CP
    Eur J Cancer; 1997 Oct; 33(12):2002-6. PubMed ID: 9516842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.